ICD-10-PCS › X New Technology › XW Anatomical Regions › XW0 New Technology, Anatomical... › XW04378
XW04378
Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
ValidICD-10-PCS procedure code.
Valid for claims with a date of service in the current code year.
What has happened to this code
Every change the publisher made, from 2023 to now.
- FY2023 Added to the code set Introduction of Tabelecleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 8
What this code says
Each character is read in its own position, so the same letter means different things in different places. Definitions are CMS's own.
3. Root operation Introduction
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
5. Approach Percutaneous
Entry, by puncture or minor incision, of instrumentation through the skin or mucous membrane and any other body layers necessary to reach the site of the procedure
6. Device / Substance / Technology Coagulation Factor Xa, Inactivated
For example
- Andexanet Alfa, Factor Xa Inhibitor Reversal Agent
- Andexxa
- Coagulation Factor Xa, (Recombinant) Inactivated
- Factor Xa Inhibitor Reversal Agent, Andexanet Alfa
Codes in the same group
| Code | Description | Status |
|---|---|---|
| XW00X27 | Introduction of Anacaulase-bcdb into Skin, External Approach, New Technology Group 7 | Retired |
| XW01318 | Introduction of Daratumumab and Hyaluronidase-fihj into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW01329 | Introduction of Talquetamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |
| XW01348 | Introduction of Teclistamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 8 | Valid |
| XW0134C | Introduction of Elamipretide into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 12 | Valid |
| XW0136A | Introduction of Dasiglucagon into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 10 | Valid |
| XW01397 | Introduction of Satralizumab-mwge into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 7 | Retired |
| XW013F5 | Introduction of Other New Technology Therapeutic Substance into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 5 | Valid |
| XW013G6 | Introduction of REGN-COV2 Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013H6 | Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013K6 | Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6 | Valid |
| XW013L9 | Introduction of Elranatamab Antineoplastic into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 9 | Valid |